This high incidence of brain involvement in both EGFR-mutated and ALK-rearranged NSCLC highlights a fundamental biological characteristic: these specific driver mutations are not merely oncogenic drivers but also appear to confer an inherent biological advantage to cancer cells for colonizing the central nervous system. This evidence concerns the gene ALK and non-small cell lung carcinoma.